Ascentage Pharma Group (AAPG) reported a 2024 loss Thursday of 1.34 renminbi ($0.18) per diluted share, narrower than a loss of 3.28 renminbi a year earlier.
Revenue for the year ended Dec. 31 was 980.7 million renminbi compared with 222 million renminbi a year earlier.
Analyst estimates were not available for comparison.
As of Dec. 31, 2024, cash and bank balances were 1.26 billion renminbi, compared to 1.09 billion renminbi a year earlier.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。